Question

Transdermal nicotine (nicotine patches) is the most widely used tobacco dependence treatment in the United States. A relative new nicotine replacement treatment is the nicotine lozenge. An effectiveness trial coordinated by the Community Clinical Oncology Program compares both treatments along different factors. The sample consisted of 642 treatment-seekers smokers randomized to receive either transdermal nicotine or nicotine lozenge for 12 weeks. Of the 321 patients receiving transdermal nicotine, 78 patients reported not smoking after 6 months; whereas of the 321 patients receiving nicotine lozenge as treatment, 60 patients reported not smoking after 6 months. Is the statistics true?

A. True
B. False

Answer 1

The truth of the statistics regarding the comparison of transdermal nicotine and nicotine lozenges in smoking cessation cannot be verified without a proper source. The provided data suggest a trial comparing the efficacy of both methods, with transdermal nicotine slightly ahead after 6 months.

Step-by-step explanation:

The statistics presented in the question concerning the efficacy of transdermal nicotine (nicotine patches) and nicotine lozenges in helping treatment-seeking smokers to quit smoking cannot be verified as true without an official source. The question appears to provide data from a clinical trial comparing the effectiveness of both treatments. According to the question, 78 out of 321 patients using transdermal nicotine reported not smoking after 6 months, whereas 60 out of 321 patients using nicotine lozenges reported the same.

Nicotine replacement therapy is widely used to combat nicotine addiction and includes products like patches, gums, and lozenges. Smoking cessation aids are intended to diminish withdrawal symptoms, increasing the likelihood of quitting. However, despite the temporary relief provided, many individuals may relapse into smoking within a year of trying nicotine replacement therapy.